SK12992001A3 - Použitie zlúčeniny a farmaceutická kompozícia ju obsahujúca - Google Patents

Použitie zlúčeniny a farmaceutická kompozícia ju obsahujúca Download PDF

Info

Publication number: SK12992001A3
Authority: SK; Slovakia
Prior art keywords: cyclobutyl; compound; methyl; chlorophenyl; formula
Prior art date: 1999-03-19

Application number

SK1299-2001A

Other languages

English (en)

Slovak (sk)

Inventor

Carl M. Mendel

Timothy B. Seaton

Original Assignee

Knoll Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-19

Filing date

2000-03-17

Publication date

2002-03-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22418412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK12992001(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-03-17 Application filed by Knoll Gmbh filed Critical Knoll Gmbh

2002-03-05 Publication of SK12992001A3 publication Critical patent/SK12992001A3/sk

Links

208000030814 Eating disease Diseases 0.000 title claims abstract description 11
208000019454 Feeding and Eating disease Diseases 0.000 title claims abstract description 11
235000014632 disordered eating Nutrition 0.000 title claims abstract description 11
238000000034 method Methods 0.000 title description 12
150000001875 compounds Chemical class 0.000 claims abstract description 61
150000003839 salts Chemical class 0.000 claims abstract description 15
206010006550 Bulimia nervosa Diseases 0.000 claims abstract description 7
230000004584 weight gain Effects 0.000 claims abstract description 7
235000019786 weight gain Nutrition 0.000 claims abstract description 7
208000032841 Bulimia Diseases 0.000 claims abstract description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 5
230000005586 smoking cessation Effects 0.000 claims abstract description 4
UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims description 16
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
201000010099 disease Diseases 0.000 claims description 8
239000008194 pharmaceutical composition Substances 0.000 claims description 8
PLXKZKLXYHLWHR-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-n,3-dimethylbutan-1-amine Chemical compound C=1C=C(Cl)C=CC=1C1(C(CC(C)C)NC)CCC1 PLXKZKLXYHLWHR-UHFFFAOYSA-N 0.000 claims description 7
206010020710 Hyperphagia Diseases 0.000 claims description 6
235000020830 overeating Nutrition 0.000 claims description 6
208000022531 anorexia Diseases 0.000 claims description 5
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
206010061428 decreased appetite Diseases 0.000 claims description 5
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 5
KFNNPQDSPLWLCX-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-n,n,3-trimethylbutan-1-amine;hydron;chloride;hydrate Chemical compound O.Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 KFNNPQDSPLWLCX-UHFFFAOYSA-N 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
WQSACWZKKZPCHN-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutan-1-amine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N)CC(C)C)CCC1 WQSACWZKKZPCHN-UHFFFAOYSA-N 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
UWAOJIWUVCMBAZ-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-dimethylazanium;chloride Chemical compound Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UWAOJIWUVCMBAZ-UHFFFAOYSA-N 0.000 claims 2
230000004044 response Effects 0.000 claims 1
208000000103 Anorexia Nervosa Diseases 0.000 abstract description 2
208000021017 Weight Gain Diseases 0.000 abstract description 2
150000004682 monohydrates Chemical class 0.000 abstract description 2
206010004716 Binge eating Diseases 0.000 abstract 1
208000014679 binge eating disease Diseases 0.000 abstract 1
239000000203 mixture Substances 0.000 description 13
239000002775 capsule Substances 0.000 description 6
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
239000003826 tablet Substances 0.000 description 6
239000002552 dosage form Substances 0.000 description 5
239000008187 granular material Substances 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000002702 enteric coating Substances 0.000 description 3
238000009505 enteric coating Methods 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000002207 metabolite Substances 0.000 description 3
210000000214 mouth Anatomy 0.000 description 3
229960004425 sibutramine Drugs 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
206010026749 Mania Diseases 0.000 description 2
208000000112 Myalgia Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 2
229960001058 bupropion Drugs 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
229960003914 desipramine Drugs 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
229960002464 fluoxetine Drugs 0.000 description 2
238000001030 gas--liquid chromatography Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
238000001802 infusion Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000004811 liquid chromatography Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000000407 monoamine reuptake Effects 0.000 description 2
239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
235000019271 petrolatum Nutrition 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
150000003141 primary amines Chemical class 0.000 description 2
-1 racemates Chemical compound 0.000 description 2
150000003335 secondary amines Chemical class 0.000 description 2
238000000926 separation method Methods 0.000 description 2
229940076279 serotonin Drugs 0.000 description 2
RLYOPPJABLAKCZ-UHFFFAOYSA-N 2-butoxycarbonylbenzenecarboperoxoic acid Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OO RLYOPPJABLAKCZ-UHFFFAOYSA-N 0.000 description 1
DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
208000008454 Hyperhidrosis Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010021030 Hypomania Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
206010034960 Photophobia Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
201000001880 Sexual dysfunction Diseases 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
208000032140 Sleepiness Diseases 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
206010003549 asthenia Diseases 0.000 description 1
238000011914 asymmetric synthesis Methods 0.000 description 1
239000002585 base Substances 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000003925 brain function Effects 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
150000005829 chemical entities Chemical class 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 1
239000000221 dopamine uptake inhibitor Substances 0.000 description 1
206010013781 dry mouth Diseases 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
239000000945 filler Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
238000003801 milling Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
230000008693 nausea Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000012053 oil suspension Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
235000019809 paraffin wax Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003380 propellant Substances 0.000 description 1
206010037844 rash Diseases 0.000 description 1
230000013275 serotonin uptake Effects 0.000 description 1
231100000872 sexual dysfunction Toxicity 0.000 description 1
229960003466 sibutramine hydrochloride Drugs 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
230000035900 sweating Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229920003002 synthetic resin Polymers 0.000 description 1
239000000057 synthetic resin Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229960004688 venlafaxine Drugs 0.000 description 1
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000001993 wax Substances 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Diabetes (AREA)
Nutrition Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Child & Adolescent Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Hydrogenated Pyridines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SK1299-2001A 1999-03-19 2000-03-17 Použitie zlúčeniny a farmaceutická kompozícia ju obsahujúca SK12992001A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US12515099P	1999-03-19	1999-03-19
PCT/US2000/007115 WO2000054765A1 (en)	1999-03-19	2000-03-17	Method of treating eating disorders

Publications (1)

Publication Number	Publication Date
SK12992001A3 true SK12992001A3 (sk)	2002-03-05

Family

ID=22418412

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1299-2001A SK12992001A3 (sk)	1999-03-19	2000-03-17	Použitie zlúčeniny a farmaceutická kompozícia ju obsahujúca

Country Status (23)

Country	Link
US (1)	US6365633B1 (de)
EP (1)	EP1178789B1 (de)
JP (1)	JP2003519087A (de)
KR (1)	KR100432825B1 (de)
CN (1)	CN1188120C (de)
AT (1)	ATE401066T1 (de)
AU (1)	AU773188C (de)
BR (1)	BR0009026A (de)
CA (1)	CA2367666C (de)
CZ (1)	CZ20013278A3 (de)
DE (1)	DE60039508D1 (de)
ES (1)	ES2307501T3 (de)
HK (1)	HK1045455B (de)
HU (1)	HUP0200495A3 (de)
IL (1)	IL145240A (de)
MX (1)	MXPA01009404A (de)
NO (1)	NO20014479L (de)
NZ (1)	NZ514011A (de)
PL (1)	PL351963A1 (de)
SK (1)	SK12992001A3 (de)
TR (1)	TR200102646T2 (de)
WO (1)	WO2000054765A1 (de)
ZA (1)	ZA200107533B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020006963A1 (en) *	1992-06-23	2002-01-17	Young James W.	Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
US20020006964A1 (en) *	1995-05-16	2002-01-17	Young James W.	Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
US6974838B2 (en)	1998-08-24	2005-12-13	Sepracor Inc.	Methods of treating or preventing pain using sibutramine metabolites
US6476078B2 (en)	1999-08-11	2002-11-05	Sepracor, Inc.	Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6399826B1 (en)	1999-08-11	2002-06-04	Sepracor Inc.	Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6610887B2 (en)	2001-04-13	2003-08-26	Sepracor Inc.	Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
US20050131074A1 (en) *	2003-08-04	2005-06-16	Beckman Kristen M.	Methods for treating metabolic syndrome
WO2005028438A1 (ja)	2003-09-22	2005-03-31	Banyu Pharmaceutical Co., Ltd.	新規ピペリジン誘導体
EP1734963A4 (de)	2004-04-02	2008-06-18	Merck & Co Inc	Verfahren zur behandlung von menschen mit metabolischen und anthropometrischen störungen
AU2005272627A1 (en) *	2004-08-13	2006-02-23	Amgen Inc.	Substituted benzofused heterocycles
ES2325773T5 (es)	2004-11-01	2014-02-24	Amylin Pharmaceuticals, Llc.	Tratamiento de la obesidad y de los trastornos relacionados
US8394765B2 (en) *	2004-11-01	2013-03-12	Amylin Pharmaceuticals Llc	Methods of treating obesity with two different anti-obesity agents
US20090286723A1 (en)	2005-02-11	2009-11-19	Amylin Pharmaceuticals, Inc.	Hybrid Polypeptides with Selectable Properties
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
NZ562766A (en)	2005-05-30	2011-03-31	Banyu Pharma Co Ltd	Piperidine derivatives as histamine-H3 receptor antagonists
EP1916239A4 (de)	2005-08-10	2009-10-21	Banyu Pharma Co Ltd	Pyridolverbindung
BRPI0614649A2 (pt)	2005-08-11	2011-04-12	Amylin Pharmaceuticals Inc	polipeptìdeos hìbridos com propriedades selecionáveis
AU2006282260A1 (en)	2005-08-24	2007-03-01	Msd K.K.	Phenylpyridone derivative
US20090264426A1 (en)	2005-09-07	2009-10-22	Shunji Sakuraba	Bicyclic aromatic substituted pyridone derivative
JPWO2007034910A1 (ja) *	2005-09-22	2009-03-26	エーザイ・アール・アンド・ディー・マネジメント株式会社	過食症及び過食症に伴ううつ病の治療用医薬組成物
US8293900B2 (en)	2005-09-29	2012-10-23	Merck Sharp & Dohme Corp	Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US20080255084A1 (en)	2005-10-21	2008-10-16	Randy Lee Webb	Combination of Organic Compounds
EP1944301A4 (de)	2005-10-27	2012-01-04	Msd Kk	Neue benzoxathiinderivate
CA2629018C (en)	2005-11-10	2013-12-31	Banyu Pharmaceutical Co., Ltd.	Aza-substituted spiro derivative
EP2698157B1 (de)	2006-09-22	2015-05-20	Merck Sharp & Dohme Corp.	Verfahren zur Behandlung von Fettsäure-Synthese-Hemmern
WO2008038692A1 (en)	2006-09-28	2008-04-03	Banyu Pharmaceutical Co., Ltd.	Diaryl ketimine derivative
CN101631859B (zh)	2007-01-16	2017-10-13	Ipintl有限责任公司	用于治疗代谢综合征的新组合物
US8106086B2 (en)	2007-04-02	2012-01-31	Msd K.K.	Indoledione derivative
MX354786B (es)	2007-06-04	2018-03-21	Synergy Pharmaceuticals Inc	Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2705708A1 (en) *	2007-11-14	2009-05-22	Amylin Pharmaceuticals, Inc.	Methods for treating obesity and obesity related diseases and disorders
EP2264026A4 (de)	2008-03-06	2012-03-28	Msd Kk	Alkylaminopyridinderivate
JPWO2009119726A1 (ja)	2008-03-28	2011-07-28	Ｍｓｄ株式会社	メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
CA2666036C (en)	2008-05-16	2017-09-12	Chien-Hung Chen	Novel compositions and methods for treating hyperproliferative diseases
CA2726917C (en)	2008-06-04	2018-06-26	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20110071129A1 (en)	2008-06-19	2011-03-24	Makoto Ando	Spirodiamine-diaryl ketoxime derivative
EP2321341B1 (de)	2008-07-16	2017-02-22	Synergy Pharmaceuticals Inc.	Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
WO2010013595A1 (ja)	2008-07-30	2010-02-04	萬有製薬株式会社	５員－５員又は５員－６員縮環シクロアルキルアミン誘導体
US8410284B2 (en)	2008-10-22	2013-04-02	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
CA2741672A1 (en)	2008-10-31	2010-05-06	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010075069A1 (en)	2008-12-16	2010-07-01	Schering Corporation	Bicyclic pyranone derivatives as nicotinic acid receptor agonists
EP2379547A1 (de)	2008-12-16	2011-10-26	Schering Corporation	Pyridopyrimidinderivate und verfahren zu deren anwendung
AU2011218830B2 (en)	2010-02-25	2014-07-24	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (en)	2011-02-25	2016-07-26	Merck Sharp & Dohme Corp.	Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
RU2015106909A (ru)	2012-08-02	2016-09-27	Мерк Шарп И Доум Корп.	Антидиабетические трициклические соединения
BR112015019836A2 (pt)	2013-02-22	2017-07-18	Merck Sharp & Dohme	composto, composição farmacêutica, e, uso de um composto
EP2970119B1 (de)	2013-03-14	2021-11-03	Merck Sharp & Dohme Corp.	Neuartige indolderivate als antidiabetika
WO2014151200A2 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja)	2013-03-15	2016-05-23	シナジーファーマシューティカルズインコーポレイテッド	グアニル酸シクラーゼのアゴニストおよびその使用
CN105764916B (zh)	2013-06-05	2021-05-18	博士医疗爱尔兰有限公司	鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
MX389591B (es)	2014-08-29	2025-03-20	Tes Pharma S R L	INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
MX2019004321A (es)	2016-10-14	2019-06-12	Tes Pharma S R L	Inhibidores de la acido alfa-amino-beta-carboximuconico semialdehido descarboxilasa.
US11072602B2 (en)	2016-12-06	2021-07-27	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
WO2018118670A1 (en)	2016-12-20	2018-06-28	Merck Sharp & Dohme Corp.	Antidiabetic spirochroman compounds
CN118496217A (zh)	2018-11-20	2024-08-16	Tes制药有限责任公司	α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2675573B2 (ja) *	1988-03-31	1997-11-12	科研製薬株式会社	脳機能改善剤
IE61928B1 (en) *	1988-11-29	1994-11-30	Boots Co Plc	Treatment of obesity
US5356934A (en) *	1990-03-29	1994-10-18	Eli Lilly And Company	Selected serotonin subtype receptor agonist to treat sleep apnea
JP2001524960A (ja) *	1997-04-24	2001-12-04	メルクシヤープエンドドームリミテツド	摂食障害を治療するためのｎｋ−１受容体拮抗薬の使用
US6331571B1 (en) *	1998-08-24	2001-12-18	Sepracor, Inc.	Methods of treating and preventing attention deficit disorders
JP2002535273A (ja) *	1999-01-20	2002-10-22	クノール・ゲー・エム・ベー・ハー	禁煙の支援方法
CA2364949A1 (en) *	1999-02-24	2000-08-31	University Of Cincinnati	Use of sulfamate derivatives for treating impulse control disorders

2000
- 2000-03-17 CA CA002367666A patent/CA2367666C/en not_active Expired - Fee Related
- 2000-03-17 NZ NZ514011A patent/NZ514011A/en not_active IP Right Cessation
- 2000-03-17 US US09/528,355 patent/US6365633B1/en not_active Expired - Fee Related
- 2000-03-17 KR KR10-2001-7011781A patent/KR100432825B1/ko not_active Expired - Fee Related
- 2000-03-17 CZ CZ20013278A patent/CZ20013278A3/cs unknown
- 2000-03-17 MX MXPA01009404A patent/MXPA01009404A/es unknown
- 2000-03-17 BR BR0009026-3A patent/BR0009026A/pt not_active Application Discontinuation
- 2000-03-17 WO PCT/US2000/007115 patent/WO2000054765A1/en not_active Ceased
- 2000-03-17 SK SK1299-2001A patent/SK12992001A3/sk unknown
- 2000-03-17 PL PL00351963A patent/PL351963A1/xx not_active Application Discontinuation
- 2000-03-17 CN CNB008074321A patent/CN1188120C/zh not_active Expired - Fee Related
- 2000-03-17 JP JP2000604841A patent/JP2003519087A/ja active Pending
- 2000-03-17 AT AT00918073T patent/ATE401066T1/de not_active IP Right Cessation
- 2000-03-17 AU AU38947/00A patent/AU773188C/en not_active Ceased
- 2000-03-17 TR TR2001/02646T patent/TR200102646T2/xx unknown
- 2000-03-17 HK HK02105308.4A patent/HK1045455B/en not_active IP Right Cessation
- 2000-03-17 IL IL145240A patent/IL145240A/en not_active IP Right Cessation
- 2000-03-17 EP EP00918073A patent/EP1178789B1/de not_active Expired - Lifetime
- 2000-03-17 ES ES00918073T patent/ES2307501T3/es not_active Expired - Lifetime
- 2000-03-17 DE DE60039508T patent/DE60039508D1/de not_active Expired - Lifetime
- 2000-03-17 HU HU0200495A patent/HUP0200495A3/hu unknown
2001
- 2001-09-12 ZA ZA200107533A patent/ZA200107533B/xx unknown
- 2001-09-14 NO NO20014479A patent/NO20014479L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
PL351963A1 (en)	2003-07-14
WO2000054765A8 (en)	2002-05-23
ATE401066T1 (de)	2008-08-15
EP1178789A1 (de)	2002-02-13
ZA200107533B (en)	2002-12-12
WO2000054765A1 (en)	2000-09-21
AU773188B2 (en)	2004-05-20
CA2367666C (en)	2008-11-25
NO20014479D0 (no)	2001-09-14
KR20020063107A (ko)	2002-08-01
AU773188C (en)	2006-01-05
HUP0200495A3 (en)	2004-09-28
IL145240A0 (en)	2002-06-30
DE60039508D1 (de)	2008-08-28
CN1188120C (zh)	2005-02-09
HK1045455B (en)	2009-04-09
IL145240A (en)	2007-02-11
KR100432825B1 (ko)	2004-05-24
CZ20013278A3 (cs)	2002-07-17
NO20014479L (no)	2001-11-02
EP1178789A4 (de)	2004-02-18
ES2307501T3 (es)	2008-12-01
NZ514011A (en)	2001-09-28
US6365633B1 (en)	2002-04-02
JP2003519087A (ja)	2003-06-17
EP1178789B1 (de)	2008-07-16
AU3894700A (en)	2000-10-04
TR200102646T2 (tr)	2002-08-21
CA2367666A1 (en)	2000-09-21
HK1045455A1 (en)	2002-11-29
BR0009026A (pt)	2003-03-05
HUP0200495A2 (en)	2002-08-28
CN1365276A (zh)	2002-08-21
MXPA01009404A (es)	2004-03-19

Publication	Publication Date	Title
SK12992001A3 (sk)	2002-03-05	Použitie zlúčeniny a farmaceutická kompozícia ju obsahujúca
US6376554B1 (en)	2002-04-23	Method of treating sexual dysfunction
US6376553B1 (en)	2002-04-23	Treatment of pain
SK13352001A3 (sk)	2002-03-05	Použitie zlúčeniny na výrobu liečiva na kontrolu prírastku hmotnosti spojeného s terapeutickými liečivami
US6355685B1 (en)	2002-03-12	Method of treating anxiety disorders
US6376551B1 (en)	2002-04-23	Treatment of chronic fatigue syndrome
SK285308B6 (sk)	2006-10-05	Liečivo na liečenie porúch spánku
US6372797B1 (en)	2002-04-16	Treatment of menstrual function
US6441046B1 (en)	2002-08-27	Control of metabolism
US6380260B1 (en)	2002-04-30	Treatment to lower platelet adhesiveness
SK13342001A3 (sk)	2002-04-04	Použitie zlúčeniny a farmaceutická kompozícia ju obsahujúca
US6365632B1 (en)	2002-04-02	Treatment of orthostatic hypotension
US6288125B1 (en)	2001-09-11	Treatment of hiatial hernia
CZ20013279A3 (cs)	2002-07-17	Farmaceutická kompozice
US20020132856A1 (en)	2002-09-19	Treatment of premenstrual syndrome
SK13372001A3 (sk)	2002-07-02	Použitie zlúčeniny a farmaceutická kompozícia ju obsahujúca
WO2000056151A1 (en)	2000-09-28	Method of treating obsessive-compulsive disorder
SK13362001A3 (sk)	2002-07-02	Použitie zlúčeniny a farmaceutická kompozícia ju obsahujúca
US20030013735A1 (en)	2003-01-16	Weight loss after pregnancy